SEC Filing Analysis: TELA Bio, Inc. (TELA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director received a routine equity compensation package, establishing their first direct holdings in the company through a grant of Restricted Stock Units (RSUs) and stock options.
• Market Impact: Negligible. The total potential dilution from the combined grants is less than 0.1% of shares outstanding, which is immaterial for a company with a $50 million market capitalization.

Company Information

Field	Value
Company	TELA Bio, Inc.
Ticker Symbol	TELA
CIK	0001561921
Industry	Surgical & Medical Instruments & Apparatus

Insider Information

Field	Value
Name	Plovanic William J.
CIK	0001685640
Title/Position	null
Relationship	Director

Transaction Details

This filing reported two grants: 11,925 RSUs and an option to buy 17,550 shares. The details below pertain to the RSU grant.

Field	Value
Form Type	4
Transaction Date	2025-10-31
Transaction Code	A (Grant)
Security Type	Common Stock (as RSUs)
Shares Involved	11,925
Price Per Share	$0.00
Total Value	$0
Shares Owned After	11,925
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0 (Grant)
% of Market Cap	0.0%
Shares Transacted	11,925
% of Shares Outstanding	0.03%
Post-Transaction Ownership	11,925 shares (0.03% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The grant is a standard component of director compensation and is insignificant relative to the company's $50 million market cap.
• Ownership Concentration: This transaction establishes the director's initial equity position in the company, aligning their interests with shareholders, albeit at a very low level (0.03% ownership).
• Dilution Impact: The combined grants (11,925 RSUs and 17,550 options) total 29,475 potential new shares. This represents a potential dilution of just 0.074% against 39.6 million shares outstanding, which is minimal.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Equity grants to directors are a routine part of compensation and do not provide new information to the market. The size of the grant is too small to be considered a significant signal.

Volume & Sentiment

• Expected Volume Impact: None. This is a non-market transaction that will not directly influence trading volume.
• Sentiment Indicator: Neutral. The filing confirms standard corporate governance practices regarding compensation.

Additional Context

Transaction Notes

• RSU Vesting: The 11,925 RSUs vest in three equal annual installments starting October 31, 2026.
• Stock Option Grant: A concurrent grant of options to purchase 17,550 shares at an exercise price of $1.23 was also reported. These options vest in 36 equal monthly installments and expire in 10 years.
• Purpose: Both grants are long-term incentives designed to retain the director and align their interests with the company's long-term performance.